Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors

Br J Haematol. 2018 Sep;182(5):718-723. doi: 10.1111/bjh.14857. Epub 2017 Aug 2.
No abstract available

Keywords: Bruton tyrosine kinase; follicular lymphoma; ibrutinib.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adult
  • Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors*
  • Agammaglobulinaemia Tyrosine Kinase / genetics*
  • Aged
  • Benzamides / pharmacology
  • Benzamides / therapeutic use
  • Disease Progression
  • Drug Resistance
  • Female
  • Humans
  • Lymphoma, Follicular / genetics
  • Lymphoma, Follicular / therapy*
  • Male
  • Middle Aged
  • Mutation*
  • Piperidines
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • Retrospective Studies
  • Substance Withdrawal Syndrome
  • Treatment Outcome

Substances

  • Benzamides
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human
  • acalabrutinib
  • Adenine